{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:16:39Z","timestamp":1783052199460,"version":"3.54.6"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T00:00:00Z","timestamp":1530489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T00:00:00Z","timestamp":1530489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In many cancers, somatic mutations confer tumorigenesis and drug-resistance. The recently established clustered regularly interspaced short palindromic repeats (CRISPR)\/Cas9 system is a potentially elegant approach to functionally evaluate mutations in cancers. To reproduce mutations by homologous recombination (HR), the HR pathway must be functional, but DNA damage repair is frequently impaired in cancers. Imatinib is a tyrosine kinase inhibitor for BCR-ABL1 in Philadelphia chromosome-positive (Ph+) leukemia, and development of resistance due to kinase domain mutation is an important issue. We attempted to introduce the T315I gatekeeper mutation into three Ph+ myeloid leukemia cell lines with a seemingly functional HR pathway due to resistance to the inhibitor for poly (ADP) ribose polymerase1. Imatinib-resistant sublines were efficiently developed by the CRISPR\/Cas9 system after short-term selection with imatinib; resulting sublines acquired the T315I mutation after HR. Thus, the usefulness of CRISPR\/Cas9 system for functional analysis of somatic mutations in cancers was demonstrated.<\/jats:p>","DOI":"10.1038\/s41598-018-27767-6","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T13:59:10Z","timestamp":1530021550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system"],"prefix":"10.1038","volume":"8","author":[{"given":"Minori","family":"Tamai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kojika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Harama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamao","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Goi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanji","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"key":"27767_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti, G., Castagnetti, F., Gugliotta, G. & Baccarani, M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nature reviews clinical oncology 14, 141\u2013154 (2017).","journal-title":"Nature reviews clinical oncology"},{"key":"27767_CR2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England journal of medicine 344, 1031\u20131037 (2001).","journal-title":"The New England journal of medicine"},{"key":"27767_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature medicine 2, 561\u2013566 (1996).","journal-title":"Nature medicine"},{"key":"27767_CR4","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas, D. A. et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103, 4396\u20134407 (2004).","journal-title":"Blood"},{"key":"27767_CR5","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","volume":"104","author":"M Towatari","year":"2004","unstructured":"Towatari, M. et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104, 3507\u20133512 (2004).","journal-title":"Blood"},{"key":"27767_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880 (2001).","journal-title":"Science"},{"key":"27767_CR7","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472\u20133475 (2002).","journal-title":"Blood"},{"key":"27767_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831\u2013843 (2003).","journal-title":"Cell"},{"key":"27767_CR9","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare, T. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer research 65, 4500\u20134505 (2005).","journal-title":"Cancer research"},{"key":"27767_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer cell 16, 401\u2013412 (2009).","journal-title":"Cancer cell"},{"key":"27767_CR11","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","volume":"101","author":"AS Corbin","year":"2003","unstructured":"Corbin, A. S., La Rosee, P., Stoffregen, E. P., Druker, B. J. & Deininger, M. W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101, 4611\u20134614 (2003).","journal-title":"Blood"},{"key":"27767_CR12","first-page":"6395","volume":"63","author":"N von Bubnoff","year":"2003","unstructured":"von Bubnoff, N. et al. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer research 63, 6395\u20136404 (2003).","journal-title":"Cancer research"},{"key":"27767_CR13","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/sj.leu.2403416","volume":"18","author":"AJ Tipping","year":"2004","unstructured":"Tipping, A. J. et al. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia 18, 1352\u20131356 (2004).","journal-title":"Leukemia"},{"key":"27767_CR14","first-page":"5995","volume":"62","author":"C Ricci","year":"2002","unstructured":"Ricci, C. et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line. Cancer research 62, 5995\u20135998 (2002).","journal-title":"Cancer research"},{"key":"27767_CR15","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/cncr.20131","volume":"100","author":"Scappini","year":"2004","unstructured":"Scappini et al. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr\/Abl protein. Cancer 100, 1459\u20131471 (2004).","journal-title":"Cancer"},{"key":"27767_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.leukres.2008.07.023","volume":"33","author":"C Hirase","year":"2009","unstructured":"Hirase, C., Maeda, Y., Takai, S. & Kanamaru, A. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. Leukemia research 33, 450\u2013459 (2009).","journal-title":"Leukemia research"},{"key":"27767_CR17","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","volume":"285","author":"H Yuan","year":"2010","unstructured":"Yuan, H. et al. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. The Journal of biological chemistry 285, 5085\u20135096 (2010).","journal-title":"The Journal of biological chemistry"},{"key":"27767_CR18","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon, F. X. et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070\u20131079 (2000).","journal-title":"Blood"},{"key":"27767_CR19","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"FX Mahon","year":"2003","unstructured":"Mahon, F. X. et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368\u20132373 (2003).","journal-title":"Blood"},{"key":"27767_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"27767_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"27767_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nbt.2842","volume":"32","author":"JD Sander","year":"2014","unstructured":"Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature biotechnology 32, 347\u2013355 (2014).","journal-title":"Nature biotechnology"},{"key":"27767_CR23","doi-asserted-by":"crossref","unstructured":"Nickoloff J. A., Jones D., Lee S. H., Williamson E. A., Hromas R. Drugging the Cancers Addicted to DNA Repair. Journal of the national cancer institute 109 (2017).","DOI":"10.1093\/jnci\/djx059"},{"key":"27767_CR24","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1172\/JCI90825","volume":"127","author":"M Nieborowska-Skorska","year":"2017","unstructured":"Nieborowska-Skorska, M. et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. The Journal of clinical investigation 127, 2392\u20132406 (2017).","journal-title":"The Journal of clinical investigation"},{"key":"27767_CR25","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England journal of medicine 368, 2059\u20132074 (2013).","DOI":"10.1056\/NEJMoa1301689"},{"key":"27767_CR26","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1182\/blood-2002-10-3011","volume":"101","author":"E Deutsch","year":"2003","unstructured":"Deutsch, E. et al. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 101, 4583\u20134588 (2003).","journal-title":"Blood"},{"key":"27767_CR27","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2010-09-307256","volume":"118","author":"A Slupianek","year":"2011","unstructured":"Slupianek, A. et al. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood 118, 1062\u20131068 (2011).","journal-title":"Blood"},{"key":"27767_CR28","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.4161\/15384101.2014.965013","volume":"13","author":"P Podszywalow-Bartnicka","year":"2014","unstructured":"Podszywalow-Bartnicka, P. et al. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation. Cell cycle 13, 3727\u20133741 (2014).","journal-title":"Cell cycle"},{"key":"27767_CR29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005).","journal-title":"Nature"},{"key":"27767_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"27767_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine 361, 123\u2013134 (2009).","journal-title":"The New England journal of medicine"},{"key":"27767_CR32","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"27767_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nbt.3190","volume":"33","author":"T Maruyama","year":"2015","unstructured":"Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nature biotechnology 33, 538\u2013542 (2015).","journal-title":"Nature biotechnology"},{"key":"27767_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nbt.3198","volume":"33","author":"VT Chu","year":"2015","unstructured":"Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nature biotechnology 33, 543\u2013548 (2015).","journal-title":"Nature biotechnology"},{"key":"27767_CR35","doi-asserted-by":"publisher","first-page":"8536","DOI":"10.1038\/sj.onc.1206080","volume":"21","author":"N Heisterkamp","year":"2002","unstructured":"Heisterkamp, N. & Groffen, J. Philadelphia-positive leukemia: a personal perspective. Oncogene 21, 8536\u20138540 (2002).","journal-title":"Oncogene"},{"key":"27767_CR36","first-page":"2563","volume":"54","author":"J ten Hoeve","year":"1994","unstructured":"ten Hoeve, J. et al. Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer research 54, 2563\u20132567 (1994).","journal-title":"Cancer research"},{"key":"27767_CR37","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1016\/S0021-9258(17)31596-X","volume":"269","author":"T Oda","year":"1994","unstructured":"Oda, T. et al. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. The Journal of biological chemistry 269, 22925\u201322928 (1994).","journal-title":"The Journal of biological chemistry"},{"key":"27767_CR38","first-page":"1111","volume":"6","author":"KE Price","year":"2013","unstructured":"Price, K. E., Saleem, N., Lee, G. & Steinberg, M. Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. OncoTargets and therapy 6, 1111\u20131118 (2013).","journal-title":"OncoTargets and therapy"},{"key":"27767_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nature17664","volume":"533","author":"D Paquet","year":"2016","unstructured":"Paquet, D. et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR\/Cas9. Nature 533, 125\u2013129 (2016).","journal-title":"Nature"},{"key":"27767_CR40","doi-asserted-by":"publisher","first-page":"e04766","DOI":"10.7554\/eLife.04766","volume":"3","author":"S Lin","year":"2014","unstructured":"Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery. Elife 3, e04766 (2014).","journal-title":"Elife"},{"key":"27767_CR41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jbiotec.2016.11.011","volume":"241","author":"X Liang","year":"2017","unstructured":"Liang, X., Potter, J., Kumar, S., Ravinder, N. & Chesnut, J. D. Enhanced CRISPR\/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. J Biotechnol 241, 136\u2013146 (2017).","journal-title":"J Biotechnol"},{"key":"27767_CR42","doi-asserted-by":"publisher","first-page":"e0129308","DOI":"10.1371\/journal.pone.0129308","volume":"10","author":"P Bialk","year":"2015","unstructured":"Bialk, P., Rivera-Torres, N., Strouse, B. & Kmiec, E. B. Regulation of gene editing activity directed by single-stranded oligonucleotides and CRISPR\/Cas9 systems. PLoS One 10, e0129308 (2015).","journal-title":"PLoS One"},{"key":"27767_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.omtn.2016.12.012","volume":"6","author":"O Brabetz","year":"2017","unstructured":"Brabetz, O. et al. RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations. Molecular therapy nucleic acids 6, 243\u2013248 (2017).","journal-title":"Molecular therapy nucleic acids"},{"key":"27767_CR44","doi-asserted-by":"crossref","unstructured":"Shaul, O. How introns enhance gene expression. The international journal of biochemistry & cell biology (2017).","DOI":"10.1016\/j.biocel.2017.06.016"},{"key":"27767_CR45","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1155390","volume":"320","author":"R Sandberg","year":"2008","unstructured":"Sandberg, R., Neilson, J. R., Sarma, A., Sharp, P. A. & Burge, C. B. Proliferating cells express mRNAs with shortened 3\u2032 untranslated regions and fewer microRNA target sites. Science 320, 1643\u20131647 (2008).","journal-title":"Science"},{"key":"27767_CR46","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.cell.2009.06.016","volume":"138","author":"C Mayr","year":"2009","unstructured":"Mayr, C. & Bartel, D. P. Widespread shortening of 3\u2032UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673\u2013684 (2009).","journal-title":"Cell"},{"key":"27767_CR47","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ccell.2016.03.013","volume":"29","author":"MJ Bueno","year":"2016","unstructured":"Bueno, M. J. et al. Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression. Cancer cell 29, 607\u2013608 (2016).","journal-title":"Cancer cell"},{"key":"27767_CR48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.canlet.2015.02.031","volume":"360","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah, O. et al. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Cancer letters 360, 245\u2013256 (2015).","journal-title":"Cancer letters"},{"key":"27767_CR49","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.canlet.2014.10.006","volume":"356","author":"O Hershkovitz-Rokah","year":"2015","unstructured":"Hershkovitz-Rokah, O. et al. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer letters 356, 597\u2013605 (2015).","journal-title":"Cancer letters"},{"key":"27767_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ymeth.2017.03.021","volume":"121-122","author":"AM Jacobi","year":"2017","unstructured":"Jacobi, A. M. et al. Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes. Methods 121-122, 16\u201328 (2017).","journal-title":"Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27767-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27767-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27767-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:04:32Z","timestamp":1671606272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27767-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,2]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["27767"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-27767-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,2]]},"assertion":[{"value":"3 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9966"}}